Prospective multicenter clinical trial to evaluate the efficacy, safety and clinical duration of HSBL32 using the BAP technique on the face and neck

Introduction: skin bioremodeling with hybrid complexes of non-crosslinked hyaluronic acid (HA) represents a significant advance in aesthetic medicine, aimed at improving overall skin quality beyond just volumetric effects. Hyaluromax Skin Builder L® (HSBL®) is an injectable gel of HA (32 mg/ml) with lidocaine, indicated for restoring deep hydration, elasticity, and skin firmness. Objectives: to evaluate the efficacy, safety, and duration of effect of the non-crosslinked HA (32 mg/ml) gel Hyaluromax Skin Builder L® (HSBL32®) applied using the bio-aesthetic points (BAP) technique to the face (5 points) and neck (10 points) in patients with signs of skin aging. Materials and methods: a prospective, multicenter, open-label clinical trial that included 107 patients (103 completed the study), treated in two sessions (day 0 and day 30) and followed for 180 days. Efficacy was assessed using validated scales (GAIS, FACE-Q Skin Quality Module, WSRS) and standardized photographic analysis. Results: a statistically significant improvement was observed in all skin quality parameters at 90 and 180 days (p